Tata Trusts, Gilead sign MoU on viral hepatitis in India

MUMBAI: Tata Trusts today said it has signed an agreement with Gilead Sciences to explore collaboration to tackle the viral hepatitis in the country.

Under the Memorandum of Understanding (MoU), Tata Trusts and Gilead will form a joint program committee to implement activities related to prevention, awareness and education, testing and treatment of viral hepatitis, a release said.
"As part of our overall health strategy aimed at addressing communicable diseases in India, we look forward to partnering with Gilead to create unique models to reduce the prevalence of viral hepatitis," Tata Trusts Managing Trustee R Venkataramanan said.

"Viral hepatitis presents a complex public health challenge in India, and by working in partnership and pooling our expertise, we hope to identify sustainable initiatives that can have a lasting impact on the burden of disease," Gilead Executive Vice President, Commercial and Access Operations in Asia, Latin America and Africa, Corporate and Medical Affairs Gregg Alton added.

The US-headquartered Gilead is a biopharmaceutical company.